patent.fyi
Applications  /  US 2026/0356982
United States Patent Application Publication

US 2026/0356982 A1

Published
Nov 12, 2026
Filed
Sep 20, 2023
Earliest date on the face
Sep 20, 2022
Classification
C07K 16/44
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Fibronectin loop recognition

What ifWhat if loops on a fibronectin type III domain formed the peptide binding surface?
Claim language“a variable heavy chain”

Three exposed loops on the beta sandwich carry side chains selected for binding the tag peptide. Basic residues contact tag aspartates, and a hydrophobic pocket accommodates its tyrosine side chain.

1.1Single domain peptide recognition

What ifWhat if an isolated heavy-chain variable domain formed the complete peptide binding site?
Claim language“a variable light chain”

A single-domain antibody presents three recognition loops on one folded domain. Selection against immobilized tag peptide enriches domains whose loops bind the exposed tag on a fusion protein.

1.1Ankyrin repeat peptide recognition

What ifWhat if the concave surface of an ankyrin repeat protein recognized the peptide tag?
Claim language“a variable heavy chain”

Three internal ankyrin repeats present variable surface residues along a continuous concave face. Selection against the tag peptide identifies repeat proteins whose side chains contact multiple positions along the peptide.

1.1Light chain domain dimer

What ifWhat if two light-chain variable domains formed the peptide binding site?
Claim language“a variable heavy chain”

A flexible peptide linker joins two light-chain variable domains that pack as a dimer. Selection against the tag peptide identifies dimers whose adjacent loops form a shared binding surface.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Contact transfer mapping on packaging lines

A synthetic fluorescent tracer bearing the DYKDDDDK peptide coats a test article that passes through a packaging line during setup. Swabs collect material from guides, rollers, and other contact surfaces after the run. An immobilized antibody with paired heavy- and light-chain variable domains captures the tracer from each swab extract through its peptide tag. Fluorescence measurements against a tracer dilution series quantify transfer at each sampling point.

Component substitution

Single domain capture on magnetic beads

A single-domain antibody selected for binding to DYKDDDDK replaces the paired heavy- and light-chain binding domain. A terminal cysteine positioned away from the binding surface couples the single-domain antibody to maleimide-functionalized magnetic beads. The beads capture tagged proteins during mixing, and a magnet holds the beads in place during washing. Soluble DYKDDDDK competes for the binding sites and releases the captured proteins.

Parameter or scale variation

Microliter capture in parallel wells

A 384-well plate holds 20 microliters of sample and 2 microliters of a 10 milligram per milliliter suspension of magnetic beads coated with antibody against DYKDDDDK in each well. The plate mixes for 15 minutes at room temperature before a magnetic plate base collects the beads. Each well receives three 30-microliter washes followed by 10 microliters of elution buffer containing 0.5 milligrams per milliliter of soluble DYKDDDDK. After 10 minutes, the magnetic base holds the beads while the eluates transfer to a separate plate.

Tag spacing for bivalent surface binding

A synthetic calibration scaffold displays two copies of DYKDDDDK connected through separate flexible spacers. Three scaffold variants place the spacer attachment points 5, 10, or 20 nanometers apart. Each variant anchors to a sensor surface through a single attachment point, and an intact antibody with two identical tag-binding sites passes over the surface. The sensor records association and dissociation at each spacing to measure how tag separation changes antibody retention.

Combination with existing systems

Affinity capture coupled to mass spectrometry

A switching valve connects a cartridge containing immobilized antibody against DYKDDDDK to a liquid chromatography system with a mass spectrometer. The loading stream passes through the cartridge, which retains tagged proteins while unbound material flows to waste. A low-pH pulse releases the retained proteins onto a reversed-phase trap, which concentrates them and washes away salts. A solvent gradient transfers the proteins to the analytical column for separation and intact mass measurement.

Automated or data-driven variant

Sensor controlled switching of capture columns

Two columns containing immobilized antibody against DYKDDDDK connect to a feed pump through a motorized switching valve. Software periodically diverts a sample of the active column's outlet into a fluorescence assay that uses a second anti-tag antibody as a tracer and measures tag concentration by fluorescence polarization. When the measured outlet concentration exceeds five percent of the feed concentration in two consecutive readings, the controller switches the feed to the second column. A separate pump washes, elutes, and re-equilibrates the first column while the second column loads.

Specific version of a part

Linked variable domains

A heavy-chain variable domain and a light-chain variable domain from the listed sets join through a 15-residue glycine-serine linker. The linked domains pair within one polypeptide and bring their six recognition loops together at the peptide binding surface.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 7,605,237 B2
Published
Oct 20, 2009
Filed
Oct 2, 2007
Class
C07K 16/28
Document BUS 2016/0046725 A1
Published
Feb 18, 2016
Filed
Nov 5, 2013
Class
C07K 16/40
Claim 1
Document A
Document B
1.1an antigen binding domain comprising a CDRH1, a CDRH2 and/or a CDRH3 of an antigen binding domain having a variable heavy chain (VH) as defined in any one of SEQ ID NOs: 2 to 5 and a CDRL1, a CDRL2 and/or a CDRL3 of a variable light chain (VL) as defined in any one of SEQ ID NOs: 7 to 10.
An isolated antibody or antigen-binding fragment thereof, which specifically binds human interleukin-4 receptor (hIL-4R) comprising the amino acid sequence of SEQ ID NO: 1, comprising a heavy chain variable region comprising three heavy-chain CDRs, and a light chain variable region comprising three light-chain CDRs, wherein said three heavy-chain CDRs comprise the CDR1, CDR2 and CDR3 from SEQ ID NO:581, and said three light-chain CDRs comprise the CDR1, CDR2 and CDR3 from SEQ
A · US 7,605,237 B2 · claim 1
Another embodiment of the invention relates to an antigen binding protein, or an antigen binding fragment thereof, comprising a light chain variable domain of sequence SEQ ID NO. 7, or any sequence exhibiting at least 80%, preferably 85%, 90%, 95% and 98% identity with SEQ ID NO. 7; and the three heavy chain CDRs comprising the sequences SEQ ID NOs. 4, 5 and 6, or any sequence exhibiting at least 80%, preferably 85%, 90%, 95% and 98% identity with SEQ ID NOs. 4, 5 and 6.
B · US 2016/0046725 A1 · ¶ 114

An empty cell means only that no passage was reproduced there.

Statements in these documents
The human antibodies are characterized by binding to hIL-4R with high affinity and by the ability to neutralize hIL-4 activity.
A · US 7,605,237 B2 · ¶ 6
In specific embodiments, the human antibodies are capable of blocking hIL-13/hIL-13R1 complex binding to hIL-4R, and thus inhibit signaling by hIL-13.
A · US 7,605,237 B2 · ¶ 6
From one aspect, the invention relates to novel antigen binding proteins, or antigen binding fragments, capable of binding to Axl and, by inducing internalization of Axl, being internalized into the cell.
B · US 2016/0046725 A1 · ¶ 1
The invention also comprises the use of said antigen binding proteins as addressing products in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
B · US 2016/0046725 A1 · ¶ 1
Cite aspatent.fyi, US 2026/0356982 A1, claim 1, first published 2026-11-20T08:53:13-05:00, https://patent.fyi/US20260356982/, SHA-256 fa7f296d9060e4a71d867d5407fb3ceb3a74556bdfb5c6164ef65ece05d77f4e
First published
Permanent addresshttps://patent.fyi/US20260356982/
Content fingerprint (SHA-256)fa7f296d9060e4a71d867d5407fb3ceb3a74556bdfb5c6164ef65ece05d77f4e
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi